Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WRN | Q14191 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 9/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30037762 | 1.00 | WRN (0.44) | WRNMAPTBRAFGAACCR1 | |
| SCHEMBL30038151 | 1.00 | WRN (0.44) | WRNMAPTBRAFGAACCR1 | |
| SCHEMBL25037171 | 1.00 | WRN (0.44) | WRNMAPTBRAFGAACCR1 | |
| SCHEMBL30037768 | 0.93 | WRN (0.50) | WRNMAPTCCR1 | |
| SCHEMBL25037165 | 0.93 | WRN (0.50) | WRNMAPTCCR1 | |
| SCHEMBL25037179 | 0.92 | WRN (0.47) | WRNMAPTBRAFGAA | |
| SCHEMBL30039076 | 0.92 | WRN (0.47) | WRNMAPTBRAFGAA | |
| SCHEMBL25037177 | 0.92 | WRN (0.46) | WRNMAPTBRAFHSD17B10 | |
| SCHEMBL30037997 | 0.92 | WRN (0.46) | WRNMAPTBRAFHSD17B10 | |
| SCHEMBL25037276 | 0.89 | WRN (0.46) | WRNMAPTBRAFHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230046859-A1 | Bicyclic Compounds and their Uses | NOVARTIS PHARMA AG (CH) | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230046859-A1 | Bicyclic Compounds and their Uses | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R, F12 | WRN 1829/4885MAPT 2519/4885BRAF 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.